On November 19, Natera rose 4.53% in Regular Trading, trading at $303.49 per share, with turnover of $112 million.
The move coincided with continued market focus on Natera's phase 2 clinical collaboration with Incyte in colorectal cancer, where Signatera is being used for primary and secondary endpoints and is also planned to help guide patient enrollment, reinforcing expectations for its application in molecular residual disease monitoring.
Supporting context remains constructive: Natera previously reported third-quarter revenue of $794.0 million, above market expectations, and raised full-year revenue guidance to $3.005 billion to $3.035 billion. At the same time, a loss of $0.42 per share, along with share resale registration and prior director selling disclosures, had weighed on sentiment, making the latest clinical progress a more visible near-term support for the stock.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments